Objectif In the field of orthopedics and maxillo-facial surgeries, there is still no satisfying solution to repair critical size bone defects. Autograft, which is the current gold standard, presents several drawbacks, including prolonged pain on donor site and higher infection risks. It needs to be replaced by efficient, safe and easy-to-use strategies. Some synthetic bone grafts are providing mechanical and osteoconductive properties, but there is a need to introduce a bioactive molecules, such as a growth factor or a peptide, to trigger actively bone repair. These “orthobiologics” products are appealing since they trigger stem cell activation in situ. There are several approved products containing orthobiologics on the market for bone regeneration, but the physiological delivery of orthobiologics remains a challenge: severe adverse effect have been reported due to the supra-physiological dose of biologics used. In addition these product do not provide structural properties which is necessary for critical size defect reconstruction. Ideally the carrier for the bioactive molecules should be appropriate and enable a spatially/temporally-controlled molecules delivery with physiological dose.Our nanomedicine technology consists of an osteoinductive biomimetic films that can be deposited on architectured implant of any shape and material (ceramics, polymers, metals). The aim of REGENERBONE is to advance our technology toward a clinical application in maxilla-facial surgery and orthopedics. This will be done by conducting pre-clinical trials in large animals, doing a market search, securing the sourcing of the film components and building a business model. The successful results we obtained recently in the frame of the ERC BIOMIM and Proof-of-Concept OSCODI are the basis for REGENERBONE, which goes a step beyond in the long process of introducing an innovative medical device to the market in an era of personalized medicine. Champ scientifique medical and health sciencesclinical medicinesurgerymedical and health sciencesmedical biotechnologynanomedicinemedical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health scienceshealth sciencespersonalized medicinemedical and health sciencesmedical biotechnologyimplantsartificial bone Mots‑clés implants bone repair nanomedicine biomimetic coating personnalized medicine scaffold growth factor Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Thème(s) ERC-2017-PoC - ERC-Proof of Concept Appel à propositions ERC-2017-PoC Voir d’autres projets de cet appel Régime de financement ERC-POC - Proof of Concept Grant Institution d’accueil INSTITUT POLYTECHNIQUE DE GRENOBLE Contribution nette de l'UE € 138 497,96 Adresse AVENUE FELIX VIALLET 46 38031 Grenoble Cedex 1 France Voir sur la carte Région Auvergne-Rhône-Alpes Rhône-Alpes Isère Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 149 998,71 Bénéficiaires (2) Trier par ordre alphabétique Trier par contribution nette de l'UE Tout développer Tout réduire INSTITUT POLYTECHNIQUE DE GRENOBLE France Contribution nette de l'UE € 138 497,96 Adresse AVENUE FELIX VIALLET 46 38031 Grenoble Cedex 1 Voir sur la carte Région Auvergne-Rhône-Alpes Rhône-Alpes Isère Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 149 998,71 Tiers Entité juridique autre qu’un sous-traitant qui est affiliée ou juridiquement liée à un participant. L’entité réalise des travaux dans les conditions prévues par la convention de subvention, fournit des biens ou des services pour l’action, mais n’a pas signé la convention de subvention. Le tiers respecte les règles applicables au participant qui lui est lié dans le cadre de la convention de subvention en ce qui concerne l’éligibilité des coûts et le contrôle des dépenses. CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS France Contribution nette de l'UE € 11 500,75 Adresse RUE MICHEL ANGE 3 75794 Paris Voir sur la carte Région Ile-de-France Ile-de-France Paris Type d’activité Research Organisations Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 11 500,75
